A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers

Journal of Infectious Diseases

Volumn 203, Issue 8, 2011, Pages 1165-1173

  Spearman, Paul ^a   Lally, Michelle A ^b   Elizaga, Marnie ^c   Montefiori, David ^d   Tomaras, Georgia D ^d   McElrath, M Juliana ^c   Hural, John ^c   De Rosa, Stephen C ^c   Sato, Alicia ^c   Huang, Yunda ^c   Frey, Sharon E ^e   Sato, Paul ^f   Donnelly, John ^g   Barnett, Susan ^g   Corey, Lawrence J ^c  

^a EMORY UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS 1 ENVELOPE GLYCOPROTEIN VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MICROSPHERE; NEUTRALIZING ANTIBODY; PLACEBO; POLYGLACTIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; MULTICENTER STUDY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ADULT; AIDS VACCINES; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; CD4-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPE MAPPING; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; VACCINES, SYNTHETIC;

EID: 79953320203     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq175     Document Type: Article

References (36)

1. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-65.
2. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, doubleblind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-71.
3. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a doubleblind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-93.
4. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20.
5. Srivastava IK, Stamatatos L, Kan E, et al. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J Virol 2003; 77:11244-59.
6. Barnett SW, Srivastava IK, Ulmer JB, Donnelly JJ, Rappuoli R. Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C. Microbes Infect 2005; 7:1386-91.
7. Dubensky TW Jr., Driver DA, Polo JM, et al. Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J Virol 1996; 70:508-19.
8. O'Hagan D, Singh M, Ugozzoli M, et al. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J Virol 2001; 75:9037-43.
9. Singh M, Briones M, Ott G, O'Hagan D. Cationic microparticles: A potent delivery system for DNA vaccines. Proc Natl Acad Sci U S A 2000; 97:811-6.
10. Srivastava IK, Stamatatos L, Legg H, et al. Purification and characterization of oligomeric envelope glycoprotein from a primary r5 subtype B human immunodeficiency virus. J Virol 2002; 76:2835-47.
11. Ansaldi F, Canepa P, Parodi V, et al. Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of crossprotection. Vaccine 2009; 27:3345-8.
12. Gupta RK, Siber GR. Adjuvants for human vaccines-current status, problems and future prospects. Vaccine 1995; 13:1263-76.
13. Russell ND, Hudgens MG, Ha R, Havenar-Daughton C, McElrath MJ. Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J Infect Dis 2003; 187:226-42.
14. Horton H, Thomas EP, Stucky JA, et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen- specific T cells induced by vaccination. J Immunol Methods 2007; 323:39-54.
15. Goepfert PA, Tomaras GD, Horton H, et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 2007; 25:510-8.
16. Tomaras GD, Yates NL, Liu P, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 2008; 82:12449-63.
17. Montefiori DC. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol 2009; 485:395-405.
18. Li M, Gao F, Mascola JR, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005; 79:10108-25.
19. Agresti A, Coull BA. Order-restricted tests for stratified comparisons of binomial proportions. Biometrics 1996; 52:1103-11.
20. Decker JM, Bibollet-Ruche F, Wei X, et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 2005; 201:1407-19.
21. Stamatatos L, Cheng-Mayer C. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. J Virol 1998; 72:7840-5.
22. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, Sodroski J. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 1995; 69:5723-33.
23. Wyatt R, Kwong PD, Desjardins E, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998; 393:705-11.
24. Barnett SW, Lu S, Srivastava I, et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 2001; 75:5526-40.
25. Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326:285-9.
26. Dhillon AK, Donners H, Pantophlet R, et al. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 2007; 81:6548-62.
27. Li Y, Svehla K, Louder MK, et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 2009; 83:1045-59.
28. Sather DN, Armann J, Ching LK, et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 2009; 83:757-69.
29. Scheid JF, Mouquet H, Feldhahn N, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009; 458:636-40.
30. Binley JM, Lybarger EA, Crooks ET, et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 2008; 82:11651-68.
31. Li Y, Migueles SA, Welcher B, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007; 13:1032-4.
32. Burke B, Gomez-Roman VR, Lian Y, et al. Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits. Virology 2009; 387:147-56.
33. Srivastava IK, Kan E, Sun Y, et al. Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates. Virology 2008; 372:273-90.
34. Otten GR, Schaefer M, Doe B, et al. Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J Virol 2005; 79:8189-200.
35. O'Hagan D, Singh M, Ugozzoli M, et al. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J Virol 2001; 75:9037-43.
36. Vajdy M, Singh M, Kazzaz J, et al. Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. AIDS Res Hum Retroviruses 2004; 20:1269-81.